UnitedHealth stock triggers strongest bullish signal in over 15 years

UnitedHealth (UNH) has reached oversold levels on weekly and monthly RSI charts not seen since 2008, currently at 27.78, after a near 30% drop from $600 to $295 driven by the abrupt CEO resignation, suspended 2025 financial outlook due to rising medical costs, and a DOJ criminal investigation into Medicare Advantage billing practices; despite insider buying boosting confidence, Wall Street remains skeptical, with Truist and TD Cowen cutting price targets to $360 and $308 respectively.

Analysis

UnitedHealth (UNH) shares have plunged nearly 30% from approximately $600 to $295 within a month, triggering a significant technical bullish signal as its weekly and monthly Relative Strength Index (RSI) dropped to 27.78, a level indicative of deeply oversold conditions not witnessed since the 2008 financial crisis; RSI readings below 30 often signal a stock is poised for a rebound. This precipitous decline was driven by a confluence of negative catalysts, including the abrupt resignation of CEO Andrew Witty on May 13, the subsequent suspension of the company's 2025 financial outlook due to soaring medical costs, particularly within Medicare Advantage plans, and unexpectedly high care demand. Compounding these issues, a Wall Street Journal report on May 15 revealed a DOJ criminal investigation into UnitedHealth’s Medicare Advantage billing practices. Despite these significant headwinds, the return of former CEO Stephen Hemsley, who expressed confidence in long-term growth, and recent insider share purchases have reportedly boosted investor confidence somewhat. However, Wall Street analysts remain skeptical of the near-term outlook: Truist, while maintaining a "Buy" rating, slashed its price target from $580 to $360, citing the suspended guidance, leadership changes, and escalating Medicare Advantage costs. Similarly, TD Cowen downgraded UNH to "Hold" and reduced its price target from $520 to $308, attributing the decision to coding pressures, regulatory changes, margin struggles, and the DOJ probe.

Key Decisions for Investors

• Given the deeply oversold technicals (RSI 27.78) and recent insider buying, investors might consider the potential for a short-term rebound, but must carefully weigh this against significant fundamental headwinds including the CEO transition and DOJ investigation.
• Closely monitor updates on the DOJ criminal probe, trends in medical costs, especially within Medicare Advantage, and any new financial guidance from the company, as these will be critical determinants of future stock performance.
• The substantial price target reductions by Wall Street analysts, including Truist's cut to $360 (maintaining "Buy") and TD Cowen's to $308 (downgrading to "Hold"), signal heightened near-term uncertainty and revised expectations, warranting a cautious stance despite the oversold conditions.
• Investors should re-evaluate current positions in UNH to ensure they align with an increased risk profile stemming from suspended guidance, leadership instability, and ongoing regulatory pressures.